HomeClinical TopicsSingle-dose IV Zofran pulled from market

Single-dose IV Zofran pulled from market


On Dec. 4, the U.S. Food and Drug Administration announced that the 32 mg, single IV dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed. The dose has been associated with prolonged QT interval, which can lead to Torsades de Pointes, which can be fatal. Read more.


Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

uterine fibroids

Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment?

A research team out of Poland recently undertook a comprehensive examination of published data to determine the role that vitamins and diet might play...